Background: CD45RO is an isoform of CD45, a protein tyrosine phosphatase that regulates T cell receptor and B cell receptor signaling pathways. CD45RO is the shortest of the eight isoforms and is expressed on activated and memory T cells and is absent from naive T cells, making CD45RO a useful marker for differentiating T cell subsets. CD45RO is also expressed on B cell subsets, activated monocytes and macrophages. CD45RO may have prognostic value in certain cancers, including non-small cell lung cancer.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis using the appropriate positive and negative tissue field of views. These results are pathologist verified.

Recommended Usage: Human FFPE: 1:100 dilution. For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI™ Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References

• Paulsen, E.E., Kilvaer, T., Khanehkenari, M.R., Maurseth, R.J., Al-Saad, S., Hald, S.M., Al-Shibli, K., Andersen, S., Richardsen, E., Busund, L.T., Bremnes, R., Donnem, T. CD45RO(+) Memory T Lymphocytes–a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer. Neoplasia. 2015;17(11):839-48.

* Conjugate tested on human and mouse FFPE tissue.